LPTX Research and Charts

LPTX - Leap Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-16 (Delayed quote data 2025-04-04)

Last 0.27	Change ⇓ -0.04 (0.00%)	Volume 904,149
	Open 0.31	High 0.31	Low 0.22

8EMA (Daily) 0.32	40EMA (Daily) 0.62	50EMA (Daily) 0.77	STO (Daily) 9.353	MACD Hist (Daily) 0.037
8EMA (Weekly) 0.571	40EMA (Weekly) 1.88	50EMA (Weekly) 2.09	STO (Weekly) 0.736	MACD Hist (Weekly) -0.243


Company Profile
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204, P205, and P103.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.